Breckenridge Pharmaceutical Inc. has launched duloxetine delayed-release capsules, a medication for depression.


Breckenridge Pharmaceutical, duloxetine delayed-release capsules, Cymbalta, Eli Lilly, major depressive disorder, medication for depression, Laboratorios Dr. Esteve S.A.












































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Breckenridge brings Cymbalta generic to market

June 13th, 2014

BOCA RATON, Fla. – Breckenridge Pharmaceutical Inc. has launched duloxetine delayed-release capsules, a medication for depression.

Breckenridge said Thursday that its product, which received final approval from the Food and Drug Administration, is being manufactured and supplied by its parent company, Laboratorios Dr. Esteve S.A. in Barcelona, Spain, and will be available in strengths of 20 mg, 30 mg and 60 mg.

Duloxetine delayed-release capsules are AB-rated to Eli Lilly & Co.'s Cymbalta, which is indicated for the treatment of major depressive disorder.

According to Breckenridge, this milestone signifies the first vertically integrated product developed and commercialized between Breckenridge and Esteve. 

More Supplier News Breaks >>
Advertisement